Japan Slow To Accept Generics, Endangering Switchover Goal
This article was originally published in PharmAsia News
Japan faces a failure in reaching its goal of nearly a third of medicines being generic by fiscal year 2012
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.